Adjustment of Insulin Pump Settings in Type 1 Diabetes Management: Advisor Pro Device Compared to Physicians' Recommendations.


Journal

Journal of diabetes science and technology
ISSN: 1932-2968
Titre abrégé: J Diabetes Sci Technol
Pays: United States
ID NLM: 101306166

Informations de publication

Date de publication:
Mar 2022
Historique:
pubmed: 27 10 2020
medline: 23 3 2022
entrez: 26 10 2020
Statut: ppublish

Résumé

To compare insulin dose adjustments made by physicians to those made by an artificial intelligence-based decision support system, the Advisor Pro, in people with type 1 diabetes (T1D) using an insulin pump and self-monitoring blood glucose (SMBG). This was a multinational, non-interventional study surveying 17 physicians from 11 countries. Each physician was asked to provide insulin dose adjustments for the settings of the pump including basal rate, carbohydrate-to-insulin ratios (CRs), and correction factors (CFs) for 15 data sets of pumps and SMBG of people with T1D (mean age 18.4 ± 4.8 years; eight females; mean glycated hemoglobin 8.2% ± 1.4% [66 ± 11mmol/mol]). The recommendations were compared among the physicians and between the physicians and the Advisor Pro. The study endpoint was the percentage of comparison points for which there was an agreement on the direction of insulin dose adjustments. The percentage (mean ± SD) of agreement among the physicians on the direction of insulin pump dose adjustments was 51.8% ± 9.2%, 54.2% ± 6.4%, and 49.8% ± 11.6% for the basal, CR, and CF, respectively. The automated recommendations of the Advisor Pro on the direction of insulin dose adjustments were comparable )49.5% ± 6.4%, 55.3% ± 8.7%, and 47.6% ± 14.4% for the basal rate, CR, and CF, respectively( and noninferior to those provided by physicians. The mean absolute difference in magnitude of change between physicians was 17.1% ± 13.1%, 14.6% ± 8.4%, and 23.9% ± 18.6% for the basal, CR, and CF, respectively, and comparable to the Advisor Pro 11.7% ± 9.7%, 10.1% ± 4.5%, and 25.5% ± 19.5%, respectively, significant for basal and CR. Considerable differences in the recommendations for changes in insulin dosing were observed among physicians. Since automated recommendations by the Advisor Pro were similar to those given by physicians, it could be considered a useful tool to manage T1D.

Identifiants

pubmed: 33100030
doi: 10.1177/1932296820965561
pmc: PMC8861776
doi:

Substances chimiques

Blood Glucose 0
Glycated Hemoglobin A 0
Hypoglycemic Agents 0
Insulin 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

364-372

Références

N Engl J Med. 1993 Sep 30;329(14):977-86
pubmed: 8366922
Diabet Med. 2018 Apr;35(4):419-429
pubmed: 29356074
Lancet. 2019 Mar 16;393(10176):1138-1148
pubmed: 30808512
J Pediatr. 2009 Nov;155(5):668-72.e1-3
pubmed: 19643434
Diabetes Care. 2015 Jun;38(6):971-8
pubmed: 25998289
Diabetes Care. 2020 Jan;43(Suppl 1):S66-S76
pubmed: 31862749
Diabetes Obes Metab. 2018 Oct;20(10):2458-2466
pubmed: 29885025
Diabetes Care. 1987 Jan-Feb;10(1):1-19
pubmed: 2882967
Diabetes Technol Ther. 2019 Feb;21(2):66-72
pubmed: 30657336
Ont Health Technol Assess Ser. 2018 Feb 21;18(2):1-160
pubmed: 29541282
Diabetes Care. 2018 Sep;41(9):2026-2044
pubmed: 30093549
Pediatr Diabetes. 2018 Oct;19 Suppl 27:84-104
pubmed: 30144259
Diabetes Care. 2020 Jan;43(Suppl 1):S77-S88
pubmed: 31862750
Diabet Med. 2015 Aug;32(8):1036-50
pubmed: 25510978
Diabetes Spectr. 2016 Feb;29(1):54-7
pubmed: 26912967
Diabetes Care. 2019 Nov;42(11):2050-2056
pubmed: 31488568
Diabetes Technol Ther. 2020 Mar;22(3):169-173
pubmed: 31596132
Diabet Med. 2015 Jan;32(1):69-77
pubmed: 25204362

Auteurs

Revital Nimri (R)

The Jesse Z and Sara Lea Shafer Institute for Endocrinology and Diabetes, National Center for Childhood Diabetes, Schneider Children's Medical Center of Israel, Petah, Tikva, Israel.

Tal Oron (T)

The Jesse Z and Sara Lea Shafer Institute for Endocrinology and Diabetes, National Center for Childhood Diabetes, Schneider Children's Medical Center of Israel, Petah, Tikva, Israel.

Ido Muller (I)

DreaMed Diabetes Ltd, Petah Tiqva, Israel.

Ivana Kraljevic (I)

Department of Endocrinology and Diabetes, UHC Zagreb, School of Medicine, University of Zagreb, Zagreb, Croatia.

Montserrat Martín Alonso (MM)

Department of Pediatrics, Children's Endocrinology Unit, University Hospital of Salamanca, Spain.

Paivi Keskinen (P)

Department of Pediatrics, University Hospital of Tampere, Finland.

Tanja Milicic (T)

Clinic for Endocrinology, Diabetes and Metabolic Diseases, Clinical Center of Serbia, Faculty of Medicine University of Belgrade, Serbia.

Asaf Oren (A)

Pediatric Endocrinology and Diabetes Unit, Dana-Dwek Children's Hospital, Tel Aviv Sourasky Medical Center, Israel.
Sackler School of Medicine, Tel Aviv University, Israel.

Athanasios Christoforidis (A)

Pediatric Department, Aristotle University of Thessaloniki, Hippokratio General Hospital, Thessaloniki, Greece.

Marieke den Brinker (M)

Department of Pediatrics, Division of Pediatric Endocrinology and Diabetology, Antwerp University Hospital and University of Antwerp, Belgium.

Lutgarda Bozzetto (L)

Department of Clinical Medicine and Surgery, University of Naples "Federico II", Italy.

Andrea Mario Bolla (AM)

Diabetes Research Institute, IRCCS San Raffaele Hospital, Milan, Italy.

Michal Krcma (M)

Department of Internal Medicine, Diabetes and Endocrinology Unit, University Hospital Pilsen, Faculty of Medicine in Pilsen, Charles University, Czech Republic.

Rosa Anna Rabini (RA)

Department of Diabetology, Hospital Mazzoni, Ascoli Piceno, Italy.

Shadi Tabba (S)

Children's Hospital of the King's Daughters, Eastern Virginia Medical School, Norfolk, VA, USA.

Lizl Smith (L)

Department of Internal Medicine, Division of Endocrinology, University of Pretoria, South Africa.

Andriani Vazeou (A)

A' Department of Pediatrics, Diabetes Center, P&A Kyriakou, Athens, Greece.

Giulio Maltoni (G)

Department of Pediatrics, University Hospital of Bologna Sant'Orsola-Malpighi Polyclinic, Italy.

Elisa Giani (E)

Department of Biomedical Sciences, Humanitas Clinical and Research Center-IRCCS and Humanitas University, Milan, Italy.

Eran Atlas (E)

DreaMed Diabetes Ltd, Petah Tiqva, Israel.

Moshe Phillip (M)

The Jesse Z and Sara Lea Shafer Institute for Endocrinology and Diabetes, National Center for Childhood Diabetes, Schneider Children's Medical Center of Israel, Petah, Tikva, Israel.
Sackler School of Medicine, Tel Aviv University, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH